{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Pre-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"0"}]}],"title":"On-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"121"},{"groupId":"OG002","value":"5"}]}],"title":"Post-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"146"},{"groupId":"OG002","value":"5"}]}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"211"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"description":"Pre-treatment deaths were collected from screening visit up to the first day of treatment, for a maximum duration of 28 days. Patients who died during the screening period are considered as screen failure.\n\nOn treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 77.4 months (treatment duration ranged from 0.1 to 76.4 months).\n\nDeaths post treatment survival follow up were collected after the on- treatment period, up to approximately 6 years. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.","groups":[{"description":"Participants received dabrafenib 150 milligram (mg) HPMC capsules orally twice daily (BID), once in the morning and a second dose approximately 12 hours after the morning dose, and trametinib 2 mg once daily in the morning. Treatment was continued until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Dabrafenib + Trametinib"},{"description":"Participants received dabrafenib 150 mg HPMC capsules orally BID, once in the morning and a second dose approximately 12 hours after the morning dose, and trametinib placebo once daily in the morning. Treatment was continued until disease progression, death, unacceptable toxicity, or withdrawal of consent. Crossover to the combination therapy arm was allowed for subjects still receiving study treatment on the dabrafenib monotherapy arm after the positive result for the final OS analysis.","id":"OG001","title":"Dabrafenib + Placebo"},{"description":"Crossover Dabrafenib + Trametinib","id":"OG002","title":"Crossover Dabrafenib + Trametinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Clinical database population; all treated patients and patients who died during screening.","reportingStatus":"POSTED","timeFrame":"up to 28 days before Day 1 (Screening), up to 77.4 months (on-treatment), up to approximately 6 years (study duration)","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}